Mereo BioPharma Group plc Result of AGM (4795E)
18 July 2016 - 10:25PM
UK Regulatory
TIDMMPH
RNS Number : 4795E
Mereo BioPharma Group plc
18 July 2016
Mereo BioPharma Group plc
Result of AGM
London, 18 July 2016 - Mereo BioPharma Group plc ("Mereo" or the
"Company") (AIM:MPH), a clinical stage UK-based specialty
biopharmaceutical company focused on rare and specialty diseases,
announces that the resolution, to reappoint Ernst and Young LLP as
auditors, put to its Annual General Meeting held earlier today, was
duly passed.
Enquiries
For further information please contact
Mereo BioPharma Group plc
+44 (0)333 023 7319
Denise Scots-Knight, Chief Executive Officer
Richard Bungay, Chief Financial Officer & COO
Nominated Adviser and Joint Broker
Cantor Fitzgerald Europe
+44 (0)20 7894 7000
Phil Davies
Will Goode
Rick Thompson
Callum Butterfield
Joint Broker
RBC Capital Markets
+44 (0)20 7653 4000
Paul Tomasic
Rupert Walford
Thomas Stockman
Laura White
Financial Adviser to the Company
Evercore
+44 (0)20 7653 6000
Julian Oakley
Tom Watson
Public Relations Adviser to the Company
FTI Consulting
+44 (0)20 3727 1000
Ben Atwell
Simon Conway
Brett Pollard
About Mereo
Mereo is a UK-based specialty biopharmaceutical company focused
on the development of innovative medicines that aim to address
unmet medical needs in rare and specialty disease areas and improve
patient quality of life.
Pharmaceutical companies face increasingly difficult choices in
the allocation of internal resources to their drug development
programs. With significant P&L constraints and rich pipelines
it has become increasingly difficult for many companies to fully
fund and advance development all of their drug candidates,
especially beyond Phase 2. Mereo has been formed to take advantage
of the global pharmaceutical industry's drive for creative ways to
progress their clinical development pipelines.
Mereo's initial mid-late stage portfolio consists of three
exceptionally well characterised novel products for the treatment
of diseases with considerable unmet medical need, which it acquired
from Novartis Pharmaceuticals in July 2015. Each of these
programmes has a comprehensive dataset for both pre-clinical and
proof-of-concept clinical studies. Since that time the Company has
initiated a Phase 2 study and a Phase 2b study in relation to two
of the product candidates in 2016 and intends to commence Phase
2b/3 studies during H2 2016 for the third product candidate.
Additional product opportunities are under evaluation.
Mereo's focus is the development of innovative medicines that
have the potential to significantly transform the lives of patients
suffering from rare and other specialised conditions around the
world. To do this, the Company depends on the combination of its
team's expertise in selecting and acquiring product opportunities,
creating value in the development pipeline and structuring creative
transactions. Mereo's internal expertise is complemented by a
unique partnership with a leading global CRO, ICON.
Mereo combines the operational discipline and efficiency of a
small company with the financial resources to conduct comprehensive
clinical studies. Mereo will rapidly progress each of the products
through further value inflection points before partnering or
divesting its products. The Company also has the option to directly
commercialise products, for example in orphan disease
indications.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGAKFDBBBKDNOD
(END) Dow Jones Newswires
July 18, 2016 08:25 ET (12:25 GMT)
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Apr 2024 to May 2024
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From May 2023 to May 2024